Q1 EPS Estimates for Vivani Medical Lifted by HC Wainwright

Vivani Medical, Inc. (NASDAQ:VANI) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of Vivani Medical in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.09). HC Wainwright has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for Vivani Medical’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.30) EPS.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.50.

Vivani Medical Stock Performance

NASDAQ VANI opened at $1.08 on Friday. The firm has a market cap of $91.42 million, a price-to-earnings ratio of -2.51 and a beta of 2.16. The firm has a 50 day simple moving average of $1.22 and a 200-day simple moving average of $1.35. Vivani Medical has a one year low of $0.91 and a one year high of $1.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Tudor Investment Corp ET AL purchased a new position in shares of Vivani Medical in the 4th quarter valued at about $1,127,000. Marshall Wace LLP purchased a new stake in Vivani Medical during the fourth quarter worth approximately $174,000. State Street Corp lifted its stake in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after purchasing an additional 16,070 shares during the last quarter. Jane Street Group LLC acquired a new position in Vivani Medical in the fourth quarter valued at approximately $60,000. Finally, Renaissance Technologies LLC increased its stake in Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the last quarter. 6.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vivani Medical

In other Vivani Medical news, Director Gregg Williams bought 1,737,765 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average price of $1.14 per share, with a total value of $1,981,052.10. Following the completion of the acquisition, the director directly owned 26,564,109 shares of the company’s stock, valued at $30,283,084.26. This represents a 7.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired a total of 4,664,347 shares of company stock worth $5,666,549 in the last three months. Insiders own 46.40% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.